Please login to the form below

Not currently logged in
Email:
Password:

FDA questions wider approval of Cymbalta

FDA scientists have noted that some of the statistical methodologies used to support data for the approval of Eli Lilly's Cymbalta appear 'problematic'

Eli Lilly has submitted data to the FDA ahead of an advisory panel meeting to support approval of its antidepressant Cymbalta (duloxetine) for chronic pain, but scientists have questioned some of the statistical methodologies used to study the drug and liver side-effects.

The advisory panel meeting was originally scheduled for January 2010, but it was delayed so the FDA could review additional information it said was "relevant to the benefit risk balance for the proposed new indication." The application is for a range of pain ailments, including lower back pain.

Cymbalta is currently approved in the US for depression, diabetic nerve pain and fibromyalgia. But FDA reviewers appeared cautious about expanding the use of the drug already used by nearly 15m patients.

The drugmaker has been trying to gain approval for the new indication for more than two years. It withdrew its application in November 2008 after the FDA questioned the method and design of the trials. The application was resubmitted last year.

Three studies showed Cymbalta lowered patient-reported pain score significantly more than a placebo after three months, but reviewers noted that positive feedback from patients who later dropped out of one of the studies, possibly due to side-effects, was included.

According to reviewers, this practice could "potentially assign good pain scores to subjects who could not tolerate the drug."

18th August 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected healthcare organisations to create powerful digital experiences. We help our...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics